The new CPR guidelines emphasize continuous chest compression with minimal interruptions for ventilation and rhythm checks.

Chest Compressions Are Central in CPR Update

BY KATE JOHNSON
Elsevier Global Medical News

Improving the quality of cardiopulmonary resuscitation skills among both the lay public and health care professionals is the central theme of the American Heart Association’s new guidelines—and optimizing chest compression is the means to that end. “Push hard, push fast, allow full chest recoil after each compression, and minimize interruptions to chest compressions,” said the authors of the 2005 AHA Guidelines for CPR and ECC (emergency cardiovascular care) published in a supplement to the journal Circulation (www.circulationaha.org).

The revised guidelines are aimed at improving the survival rate for out-of-hospital cardiac arrest, which ‘remains low worldwide, averaging 5% or less,’” Mary Fran Hazinski, R.N., of Vanderbilt Children’s Hospital, Nashville, Tenn., and her colleagues noted in an accompanying summary of the key changes from the previous guidelines, issued in 2000 (Circulation 2005;112:IV2006-IV211).

While the research behind the new guidelines included debate about all aspects of detection and treatment of cardiac arrest, the last summation returned to the beginning question: How do we get more bystanders and health care providers to perform CPR and to perform it well?” they said. See CPR • page 2

Move Over, MRSA: Tough Acinetobacter Threatens Hospitals

BY KERRI WACHTER
Elsevier Global Medical News

WASHINGTON — The United States may be poised on the brink of the next drug-resistant infection epidemic, with outbreaks of Acinetobacter baumanii already appearing in hospitals nationwide, according to reports speaking at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

The spread of the bacteria has already reached epidemic proportions in Israeli and Latin American hospitals, and is a serious problem in Europe as well. In fact, “Acinetobacter has been designated as the gram-negative MRSA (methicillin-resistant Staphylococcus aureus),” said Dr. Harald Seifert, a professor at the University of Cologne’s Institute of Medical Microbiology and Hygiene.

“We’re not only dealing with an increasing incidence of multi-resistant Acinetobacter, but we seem to be dealing with an increasing absolute incidence of Acinetobacter,” said Dr. Anthony D. Harris, an epidemiologist for the University of Maryland Medical System, Baltimore.

Acinetobacter baumanii is a nonmotile, gram-negative bacterium that affects mainly immunocompromised patients, particularly patients in the ICU setting or those who have been hospitalized for long periods, Dr. Seifert said at the meeting sponsored by the American Society for Microbiology. Though the organism can cause a wide range of infections, the most common are respiratory tract, bloodstream, urinary tract, skin and soft tissue, and wound infections. In particular, it is the most important pathogen causing pneumonia in patients who are on a ventilator, Dr. Harris said.

About half of Acinetobacter infections are sepsis- or ventilator-associated pneumonias, based on data from several series, said Dr. Yehuda Carmel, head of the division of epidemiology at Vanderbilt Children’s Hospital, Nashville, Tenn., and her colleagues noted in an accompanying summary of the key changes from the previous guidelines, issued in 2000 (Circulation 2005;112:IV2006-IV211).

While the research behind the new guidelines included debate about all aspects of detection and treatment of cardiac arrest, the last summation returned to the beginning question: How do we get more bystanders and health care providers to perform CPR and to perform it well?” they said.

Note: Based on weighted national estimates from the Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample. Source: U.S. Agency for Healthcare Research and Quality.
“Our greatest challenge and highest priority is the training of lay rescuers and health care providers in simple, high-quality CPR skills that can be easily taught, recommended, and implemented,” according to Ms. Hazinski and her associates. Evidence shows that “few victims of cardiac arrest receive CPR, and even fewer receive high-quality CPR,” they said.

To address this issue, the authors recommend a simplification of previous instructions on CPR, with a stronger emphasis on continuous chest compression with minimal interruptions for ventilation and rhythm checks.

The combination of inadequate and interrupted chest compressions and excessive ventilation rates reduces cardiac output and coronary and cerebral blood flow and diminishes the likelihood of a successful resuscitation attempt, the authors said.

Thus, a universal compression-ventilation ratio of 30:2 for all tone rescuers (lay or trained) of victims of any age (including newborns) is recommended.

Children can be treated using a 15:2 ratio if there are two rescuers present, since asphyxial arrest is more likely in this population. And a priority for ventilation was reaffirmed in the case of newborn resuscitation.

From an emergency medicine perspective, “this will hopefully mean we get a lot of lay rescuers to maximize their early benefit” would seem to provide your early benefit’ would seem to provide the most benefit to the most people. Many more people who are saved are saved early, rather than late.”

The main change in the guidelines concerning defibrillation is the recommendation for only one shock rather than three, and the emphasis on immediate postshock chest compressions and CPR, rather than rhythm checks.

This change is based on the high first-shock success rate of new defibrillators and the knowledge that if the first shock fails, intervening chest compressions can improve oxygen and substrate delivery to the myocardium, making the subsequent shock more likely to result in defibrillation, explained Ms. Hazinski and her associates.

Although lay rescuers are encouraged to use automated external defibrillators as soon as possible, emergency medical service providers “may consider about five cycles (or 2 minutes) of CPR before defibrillation for witnessed arrest,” they suggested.

The first rhythm check should be done about 2 minutes after defibrillation and every subsequent 2 minutes. Vasopressors and antiaarrhythmics should be administered as soon as possible after a rhythm check.

For acute ischemic stroke, there was reaffirmation of the previous recommendation to use tissue plasminogen activator (TPA) therapy “when administered by physicians in hospitals with stroke protocols that rigorously adhere to the eligibility criteria and therapeutic regimen of the National Institute of Neurological Disorders and Stroke (NINDS) protocol,” Ms. Hazinski and her associates said.

Reaction to the guidelines from various specialties appears positive—particularly the stronger emphasis on chest compression.

We brain specialists like anything that keeps the blood flowing and keeps people pumping on the chest,” neurologist William M. Coplin said in an interview. “Once you start the heart, you can keep the brain perfused—and that’s what’s important.”

Cardiologist James J. Ferguson III agrees with the focus on chest compressions as the cornerstone of effective CPR. “One can infer that too many interruptions, ineffective circulation, and a lack of prioritization may have contributed to less than optimal outcomes in the past,” said Dr. Ferguson of Baylor College of Medicine, Houston, and the Texas Heart Institute of St. Luke’s Episcopal Hospital there.

Both Dr. Ferguson and Dr. Coplin agreed that the new guidelines may also be useful in overcoming hesitancy from bystanders who are worried about discharge-exposure with mouth-to-mouth resuscitation.

By stressing the importance of chest compressions, this may sidestep some of those issues; but it raises the concern that later on in the resuscitation efforts, when shock becomes more important, it may be ignored to some extent,” Dr. Ferguson said in an interview.

However, he said that “the workflow philosophy of ‘keep it simple and maximize your early benefit’ would seem to provide the most benefit to the most people. Many more people who are saved are saved early, rather than late.”

Dr. Coplin also agreed with the effort to simplify procedures. “This isn’t supposed to be rocket science,” he said. “The idea is to keep things under control until the rocket scientist is available.”
FROM THE EDITOR IN CHIEF

Welcome to CHEST PHYSICIAN

Medical news publications face the complex task of getting important information to readers while, at the same time, being useful and interesting. CHEST PHYSICIAN takes a giant leap to help fulfill that mandate.

Starting with this inaugural issue, the American College of Chest Physicians and the Elsevier News Group are joining forces to provide the latest clinical and practice management information available to the chest medicine community. The new CHEST PHYSICIAN delivers timely news articles in pulmonology, critical care, sleep medicine, cardiology, thoracic surgery, and other chest medicine-related specialties, covering areas such as new clinical procedures, the newest drug treatment advances, information to help you in your medical practice, and articles dealing with the critical issues facing the health care system.

Each monthly issue features a special “News From the College” section, which includes Educational Insights. The CHEST Foundation, Inside NetWorks, ACCP Institutes, Member Matters, ACCP Worldwide, This Month in CHEST—Editor’s Picks, and much more.

Additionally, Pulmonary Perspectives, under the excellent, ongoing editorship of Deborah Shure, M.D., Master FCCP, is now incorporated into CHEST PHYSICIAN. Each month brings you an article relating to the one source chest physicians and their patients can rely on to find the information they need. In the process, we hope to better prepare you for the challenges you encounter in your practice every day and assist you in providing the highest quality patient-focused care.

Send us your feedback, your thoughts, and your opinions. If you like an article, or if you disagree with an opinion voiced by a colleague, send an e-mail to chestphysiciannews@chestnet.org. This is your publication, and for us to be successful, we need your input.

As Editor in Chief, I look forward to hearing from you. I also look forward to being part of the dynamic team producing this publication. Together, we hope to bring you the latest news and most relevant clinical information available today.

Dr. Hardinger is professor of medicine at the University of Alabama at Birmingham in the division of pulmonary, allergy, and critical care medicine. She is a past awardee of the NIH-NHLBI Sleep Academic Award and the Physician-Scientist Award from the NIH.

Meet the CHEST Physician Editorial Advisory Board

Michael H. Baumann, M.D., M.S., FCCP, is professor of medicine and the director of respiratory care services in the division of pulmonary, critical care, and sleep medicine at the University of Mississippi Medical Center in Jackson. Dr. Baumann is the scientific program chair for CHEST 2006 and has served the American College of Chest Physicians in numerous leadership positions, which include chairing the Health and Science Policy Committee and the Council of Governors.

Thomas R. Behnbeck, M.D., Ph.D., FCCP, is associate professor of medicine at the Mayo Clinic in Rochester, Minn. Dr. Behnbeck is presently on the steering committee of the Cardiovascular Medicine and Surgery NetWork.

Robert J. Cerullo, M.D., FCCP, is associate professor of surgery and chief of the section of thoracic surgery at the University of Alabama at Birmingham.

Vera A. De Palo, M.D., FCCP, is associate chief of medicine and the ICU director at Memorial Hospital of Rhode Island in Pawtucket. Dr. De Palo is the past chair of the ACCP Credentials Committee, an ACCP Governor for Rhode Island, and a member of The CHEST Foundation Humanitarian Awards Review Committee.

LeRoy M. Graham, M.D., FCCP, is associate clinical professor at the Morehouse School of Medicine and works with Georgia Pediatric Pulmonology Associates, PC, in Atlanta. Dr. Graham has been very active in ACCP NetWork as previous chair of the Cultural Diversity in Medicine Network and the Pediatric Chest Medicine Network. He is currently a trustee of The CHEST Foundation and chair of the ACCP Patient Education Committee.

Jeffrey W. Hawkins, M.D., FCCP, is adjunct clinical assistant professor of medicine in the division of pulmonary, allergy, and critical care medicine at the University of Alabama at Birmingham.

Peter McKeown, M.B.B.S., FCCP, is consulting professor of surgery at Duke University and chief of surgery at Asheville VA Medical Center in North Carolina. Dr. McKeown currently serves as a Regent-at-Large on the ACCP Board of Regents, is the ACCP member for North Carolina, and is on the Marketing, Nominations, and Finance Committees.

Aymah M. Robles, M.D., FCCP, is the deputy editor of Pulmonary Perspectives, a regular feature in CHEST PHYSICIAN. Dr. Robles is currently the chair of The CHEST Foundation Pro Bono Committee and past chair of the Cultural Diversity in Medicine Network. She was a 2006 recipient of a CHEST Foundation Humanitarian Award. She resides in Miami.

George A. Sarosi, M.D., FCCP, is professor of medicine and chief of medical service at Roudebush VA Medical Center in Indianapolis. Dr. Sarosi is an active participant on the ACCP-SEEK editorial board and has served on the CHEST editorial board.

Paul A. Selecky, M.D., FCCP, is clinical professor of medicine at the University of California, Los Angeles. He is also the medical director of the pulmonary department in the Sleep Disorders Center and Palliative Medicine Service at Hoag Hospital in Newport Beach, Calif. Dr. Selecky is the immediate past chair of the ACCP Continuing Education Committee and a past president of NAMDBC. He has participated in several ACCP committees, including Ethics, Government Relations, and Health and Science Policy, and he is the current chair of the Respiratory Care NetWork.

Curtis M. Sessler, M.D., FCCP, is the Orhan Murun Professor of Medicine in the division of pulmonary, allergy, and critical care medicine at Virginia Commonwealth University in Richmond. He is also the medical director of critical care at the Medical College of Virginia Hospitals in Richmond. Dr. Sessler is the chair of the ACCP Critical Care Institute and past chair of the Critical Care NetWork. He was the program chair for CHEST 2003 and is a past ACCP Governor for Virginia.

Deborah Shure, M.D., Master FCCP, is the editor of Pulmonary Perspectives, a regular feature in CHEST PHYSICIAN. Dr. Shure is a Past President of the American College of Chest Physicians and was bestowed the honor of Master Fellow in 2000. She has served on numerous ACCP committees and has been a CHEST Foundation trustee, being active in The Foundation Pro Bono and Awards Committee. She resides in Miami.

(Not pictured)

Gerard A. Silvestri, M.D., FCCP, is associate professor of medicine at the Medical University of South Carolina in Charleston. Dr. Silvestri is a trustee of The CHEST Foundation and serves on The Foundation Development Committee. He has participated in the ACCP Thoracic Oncology and Interventional Pulmonary Procedures NetWork and the Health and Science Policy Committee.
Bacteria Resist Containment

Acinetobacter

From page 1

the Tel Aviv Sourasky Medical Center. Central nervous system infections following neurosurgery are also common. Acinetobacter outbreaks also have occurred after mammalian and natural disasters, including the 1999 earthquake in Turkey, the 2002 terrorist bombing in Bali, and the 2004 tsunami in the Pacific. The clonal nature of the outbreaks has also reported an increasing number of Acinetobacter bloodstream infections in soldiers injured in Iraq, Kuwait, and Afghanistan.

Rates Nearly Double

Between 1986 and 2002, the rate of nosocomial pneumonia infections caused by Acinetobacter almost doubled in the United States, from 4% to 7%, Dr. Seifert said. In an analysis of data from the Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) program at Cornell University, New York, there were 189 patients with a positive culture for multidrug-resistant Acinetobacter, Dr. Harris said. Outbreaks have also been reported in New York and among soldiers returning from Iraq and Afghanistan.

In Europe, Acinetobacter has been reported for 0.6% of these infections; in ICU wards, Acinetobacter accounts for up to 1% of these infections; and in non-ICU wards, the pathogen accounted for up to 10% of all bloodstream infections, earning a number 10 ranking there as well, according to the SENTRY Antimicrobial Surveillance Program, which monitors the predominant pathogens and antimicrobial resistance for both nosocomial and community-acquired infections.

Acinetobacter accounts for an even greater number of respiratory tract infections among hospitalized patients—more than 4% in Europe and 10% in Latin America. In the United States, Acinetobacter accounts for 7% of respiratory tract infections among hospitalized patients alone, Dr. Seifert said.

In Israeli hospitals, Acinetobacter ranks first or second among causes of bacteremia, Dr. Carmeli said.

Resistance Is Rising

Of particular concern is Acinetobacter resistance to an increasing number of antimicrobial agents and developing pan-resistant strains, Dr. Seifert said. Strains that are resistant to every antimicrobial class on the market are now common in some parts of the world.

“Antibiotic-resistant Acinetobacter has had a sharp increase in the last decade basically worldwide,” Dr. Harris said. Resistance has been reported for aminopenicillins, first- and second-generation cephalosporins, carbapenems, and tetracyclines, among others. Unique clones have been reported that are resistant to several drugs.

The likelihood of mismatch between chosen therapy and drug susceptibility is very high—almost 100%—because many Acinetobacter strains are multidrug resistant.

“In many cases, we don’t have any effective treatment,” Dr. Carmeli said. He relied trying as many as five antibiotics at the same time to treat patients.

“We desperately need new antibiotics for gram-negative bacteria. Few are in the pipeline,” Dr. Harris said. Those that are under investigation are related to currently approved drugs for gram-negative organisms and “are unlikely to solve some of our major, resistant, gram-negative bacterial problems, including Acinetobacter.” Mortality can be high for patients with Acinetobacter infections. According to one study of three Israeli hospitals, fatality rates for bloodstream infections caused by multidrug-resistant Acinetobacter averaged about 90% (J. Hosp. Infect. 2005;60:256-60).

Dr. Carmeli and his colleagues performed a matched case-control study of 118 patients with a positive culture for multidrug-resistant Acinetobacter (susceptibility to carbapenems, colistin, and ampicillin-sulbactam) during a 6-month period. Mortality in patients was 36%, compared with 21% in controls, for an adjusted odds ratio of 6.23. Average length of stay for patients with Acinetobacter was 28 days, compared with 17 days for controls, but the difference was not statistically significant.

“Most of the mortality, in my experience, is concentrated in patients who have either sepsis or pneumonia,” Dr. Carmeli said.

Eradication Efforts Stymied

“Another characteristic feature of Acinetobacter baumannii is the propensity for epidemic spread,” Dr. Seifert said. The organism is easily transmitted by person-to-person contact.

“One it’s established in your hospital, it’s very difficult to get rid of it,” Dr. Carmeli said. He noted that in one ICU ward in Israel, the staff was able to eliminate Clostridiom difficile and MRSA through strict infection control measures, “but did not make any change in Acinetobacter at all.”

More worrying, environmental contamination may play a role in the spread of the bacterium. Acinetobacter can live on a dry surface for a month or longer. Contamination times of 3 months have even been reported.

In Israel, not only is Acinetobacter spreading beyond ICUs as patients are moved to other wards, but the outbreaks are also polyclonal. Hospital staff must contend with more than one clone in more than one ward, making eradication virtually impossible.

Based on the current epidemiology of Acinetobacter in Israeli hospitals, Dr. Carmeli estimates that at the peak of a U.S. epidemic, physicians here could expect to see 280,000 cases each year, including 120,000 cases of pneumonia or sepsis and 30,000 cases of attributable mortality.

Also worrying is the fact that no one is clear on what interventions work to prevent the spread. A number of interventions have been attempted, but “at this point, to be rather frank, none have proved rather successful in light of the rapid spread,” Dr. Harris said.

“The same measures that worked to control things in our medical ICU did not work at all in controlling our outbreaks in shock/trauma,” he noted.

Washington — Multidrug resistance poses a serious problem for treating Acinetobacter baumannii infections, and one expert offered his thoughts on the choice of therapy at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

“Most of the problems around the world are [Acinetobacter strains] that have become resistant to everything,” said Dr. James J. Rahal, the director of the infectious disease section at New York Hospital Queens and a professor of medicine at Weill Medical College of Cornell University, New York.

The carbapenems and ampicillin-sulbactam have retained in vitro and clinical activities against Acinetobacter, but a growing number of reports have documented resistance to these drugs.

Physicians have turned to nontraditional agents, such as colistin and polymyxin B, which had lost favor in the antibiotic arsenal because of concerns about nephrotoxicity.

Dr. Rahal offered this advice:

“For susceptible Acinetobacter strains, trimethoprim-sulfamethoxazole, quinolones, and ampicillin-sulbactam may be effective as single therapies.

“Carbapenems remain the drugs of choice. It’s unclear whether combination therapy with another drug might prevent the development of resistance to the carbapenems.

“Colistin and polymyxin B have been shown to be effective clinically. “From my review, I have concluded that the efficacy is clearly less in serious pulmonary infection...so higher-than-usual doses should be considered,” Dr. Rahal said.

“The addition of rifampin to single-drug therapy should be considered.

“The contribution of rifampin to anti-gram-negative therapy has been demonstrated both clinically and in vitro for many years,” he said.

Research based on other organisms shows promise that combination therapy using two or more different classes of antibiotics results in a synergistic effect that is efficacious and may stave off bacterial resistance to single therapies.

“My inclination is that double therapy in fact might prevent the evolution of resistance, but that is a question that has been in the literature for a long time and never proven,” Dr. Rahal said at the meeting sponsored by the American Society for Microbiology.

Researchers and physicians alike have been focusing on the use of combinations of colistin, polymyxin B, rifampin, and imipenem, although other drug combinations have been considered as well.

“It seems that the most active combinations are those that add either imipenem or rifampin or both to polymyxin B,” said Dr. Rahal, based on his own research.

Another interesting aspect that has emerged is dosage, he said. The usual dosage of colistin is 5 mg/kg per day, but researchers have experimented with dosages as high as 15 mg/kg per day.

In 2005, the Food and Drug Administration approved Tygacil (tigecycline), a novel broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus. The drug shows activity in vitro against multidrug-resistant Acinetobacter, but what effect the drug will have clinically is unknown, Dr. Rahal said.

—Kerri Wachter

CDC microbiologist Janice Carr scans a specimen of Acinetobacter baumanii, whose spread has reached epidemic proportions in Latin American and Israeli hospitals.
Inhaled Corticosteroids and Fetal Growth

The widespread prescribing of corticosteroids in medicine includes many clinical situations during pregnancy, which naturally raises concerns about the safety of these drugs in pregnant women. Over the past several years, information has begun to accumulate on the safety of inhaled corticosteroids in this population.

In October, the largest study to date, conducted by the Organization of Teratology Information Services (OTIS), on the use of asthma medications—corticosteroids and β2-agonists—during pregnancy and their effects on fetal growth was published. The main finding was that treatment of pregnant women with β2-agonists—during pregnancy and incidence of SGA in 303 infants whose mothers did not have asthma. Women from North America were enrolled between 1998 and 2003. There were no significant differences in the incidence of SGA for weight between the groups. Birth weight was slightly reduced among those exposed to systemic steroids: the mean birth weight, adjusted for other risk factors, was 3,373 g, compared with a mean of 3,450 g among controls, 3,512 g among those exposed to β2-agonists only, and 3,524 g among those exposed to inhaled steroids.

Mean birth weight and mean birth length, adjusted for risk factors, among infants whose mothers had been treated with inhaled steroids were not significantly different from those of controls or of infants whose mothers had used β2-agonists only. The adjusted mean length was 51.3 cm in the inhaled steroid group and 51.5 cm in the β2-agonist group.

Over the past several years, information has begun to accumulate on the safety of these drugs in pregnant women. The prospective study compared birth size and incidence of babies born small for gestational age (SGA) in 654 infants whose mothers had taken inhaled or systemic corticosteroids and β2-agonists for asthma during pregnancy with birth size and incidence of SGA in 303 infants whose mothers did not have asthma. Women from North America were enrolled between 1998 and 2003. There were no significant differences in the incidence of SGA for weight between the groups. Birth weight was slightly reduced among those exposed to systemic steroids: the mean birth weight, adjusted for other risk factors, was 3,373 g, compared with a mean of 3,450 g among controls, 3,512 g among those exposed to β2-agonists only, and 3,524 g among those exposed to inhaled steroids.

The authors, from the University of California, San Diego and the OTIS Research Group, concluded that these results were “reassuring and support the recommendations of adequate control of severe asthma during pregnancy” and that “the modest effect of systemic steroids on fetal growth should be weighed against the necessity to achieve adequate control of severe persistent asthma and to prevent hyposia during pregnancy” (J Allergy Clin Immunol. 2003;116:503-9).

While these conclusions are not novel, this study is a major breakthrough because it combines information from teratology information centers to provide much larger numbers than were available previously. Women and physicians should be informed there are some risks: In 2000, my colleagues and I published a metaanalysis of all available studies of women given high-dose steroids during pregnancy. The results clearly indicated that the use of systemic steroids in the first trimester was associated with a two- to threefold higher risk of oral clefts (Teratology 2000;62:385-92). However, inhaled corticosteroids, commonly used as first-line therapy for asthma, result in an extremely low systemic dose, and none of the available reviews on the use of inhaled steroids during pregnancy have found any association with a greater risk of oral clefts. The β2-agonist albuterol is not teratogenic.

There is emerging evidence that repeated weekly corticosteroid injections for fetal lung maturation in cases of premature rupture of the membranes may result in brain damage in some babies. But this is not relevant to the use of inhaled corticosteroids in pregnant women with asthma.

Therefore, based on this recent study and previous data, pregnant women should be encouraged not to neglect their asthma therapy because of concerns about potential effects on the fetus.

Dr. Koren is professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto. He heads the Research Leadership in Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he is director of the Motherisk Program, a teratogen information service (www.motherisk.org).

CALL FOR RECOMMENDATIONS

ACCP International Regent Nominations

Help the ACCP International Nominations Subcommittee select nominees for International Regent, the highest ACCP leadership position in each country. ACCP International Regents have the opportunity to:

• Serve as leaders and act as role models for chest physicians in their countries.
• Recommend new policies or programs to benefit ACCP members in their countries.
• Become eligible to sit on the ACCP Board of Regents and represent all international members.

The International Nominations Subcommittee is soliciting recommendations for International Regents now in select countries. Visit www.chestnet.org to:

• Review the qualifications and requirements for International Regents.
• Check the list of countries with open positions.
• Submit your recommendation by March 31, 2006.


**Postop Infection Rate Dropped With Early Enteral Feeding**

Don’t delay feeding even in critically ill patients.

**San Francisco** — Enteral administration of the nutrient glutamine within 8 hours of major surgery boosted antioxidant production and reduced patients’ length of stay by a day, according to a Canadian study reported by Dr. Adeola O.E. Obayan at the annual clinical congress of the American College of Surgeons.

Surgery is a controlled form of trauma, the commonest cause of oxidative stress,” explained Dr. Obayan, a surgeon at the University of Saskatchewan in Saskatoon. Knowing that the loss of up to 40% of natural glutamine levels after surgery places the body in a state of oxidative stress, Dr. Obayan and associates hypothesized that providing supplemental glutamine would foster healing while preventing oxidative stress. They enrolled 69 patients undergoing elective surgery in a prospective, randomized, double-blind trial at the Royal University Hospital in Saskatoon, Sask. The surgical procedures included hepatobiliary, pancreatic, cardiorespiratory, thoracic, plastic, and oncologic surgeries, as well as neurosurgery. Half of the patients received a 3-g/kg/day glutamine supplementation (0.3 g/kg) through feeding tubes, while the others received a placebo.

Results showed that the supplemental glutamine significantly increased plasma glutamine and antioxidant levels at 24 hours; it also significantly reduced strong oxidant production.

The average length of stay was reduced by 1 day among patients receiving glutamine when the investigators accounted for the severity of patients’ illnesses and the complexity of their procedures. Resource intensity weighting analysis, a measure of cost adjusted by case complexity, found a found a profoundly significant cost savings in patients undergoing more complex procedures.

University of Saskatchewan surgeons now give oral glutamine preoperatively to patients having general or orthopedic surgery, he said.

**Glutamine Given After Surgery Cut Hospital Stays by a Day**

BY BETSY BATES

Elsevier Global Medical News

**Critical Care Medicine**

**Early Echocardiogram May Alter Shock Tx**

BY BOB BABINSKI

Elsevier Global Medical News

**MONTRÉAL** — Dr. Anthony Manasia of New York’s Mt. Sinai School of Medicine is making the case for early goal-directed cardiovascular resuscitation for patients admitted in shock to the ICU.

In a small, ongoing study, Dr. Manasia has found that early echos have had an impact on treatment in more than half of the 24 patients he has evaluated.

For his study, shock is defined as hypotension (mean arterial pressure less than 65 mm Hg or systolic blood pressure less than 90 mm Hg, or a 40% decrease in systolic blood pressure, compared with baseline) or need of vasopressor therapy following an adequate fluid challenge, associated with either hyperlactatemia, oliguria/anuria or an increase in serum creatinine.

The patients’ first echo was performed upon entry into the ICU — average time to echo from onset of shock was 5.4 hours— with a second echo taken place within the next 24 hours. All procedures were performed by an echo-trained intensivist not involved in the patient’s care.

Based on echo information (left ventricular preload and global contractility), the primary ICU team revised each patient’s medical treatment plan regarding intravenous fluid management and vasopressor therapy, Dr. Manasia said at the annual meeting of the American College of Chest Physicians. Changes in medical management were recorded following each echo and compared with decisions made after the second echo.

Dr. Manasia found that nearly 40% of patients had their initial treatment plan changed after their first echo. Another 17% had changes made after their second echo.

“Although the numbers that I present are small, I feel that changing the therapeutic intervention in 37.9% of patients in shock is important,” the author said. “Also, the use of echocardiography by intensivists will have a major impact on how they treat patients in the early phases of shock.”

The review included hospitalized adults in intensive care units with a second echo taking place within the medical consultation phase, Dr. Manasia wants to find out more.

“What needs to be studied is whether or not there is a change in outcome,” he said.

If there is a bowel, use it,” a smiling Dr. Marik recommended placement of a nasogastric or oral gastric tube on admission by case complexity, found a profound difference in mortality (dopamine 49.5%).

“Given the significant difference in the incidence of cardiac dysrhythmias associated with dopamine administration in septic shock patients, consideration should be given to using norepinephrine over dopamine as a first-line vasopressor agent in septic shock, especially in patients with a history of arrhythmia or cardiac problems,” Dr. Simon Grahe said.

Patients with a history of prior arrhythmias had a statistically significant greater likelihood of developing cardiac dysrhythmias when on vasopressors,” she said.

**Glutamine and Antioxidant Levels Increased Significantly at 24 Hours, and Strong Oxidant Production Was Reduced.**

**PLASMA GLUTAMINE AND ANTIOXIDANT LEVELS INCREASED SIGNIFICANTLY AT 24 HOURS, AND STRONG OXIDANT PRODUCTION WAS REDUCED.**

BY BOB BABINSKI

Elsevier Global Medical News

**MONTRÉAL** — A large increase in cardiovascular resuscitation was associated with dopamine, compared with norepinephrine, as a vasopressor therapy in septic shock, but there was no difference in mortality, Dr. Jaime J. Simon Grahe said at the annual meeting of the American College of Chest Physicians.

Dr. Simon Grahe and his colleagues conducted a treatment study of 66 septic shock patients in the medical ICU at Rush University, Chicago. Thirty-five patients were prospectively randomized to receive dopamine as a first-line vasopressor, and 11 were randomized to norepinephrine. Acute Physiology and Chronic Health Evaluation (APACHE II), gender, and age were all similar at baseline between the two groups. All patients were treated with early goal-directed medical therapy, including fluid resuscitation, antibiotics, tight glycemic control, and management of adrenal insufficiency, according to Dr. Simon Grahe of Rush University.

When the maximum dose of either drug was reached, “patients received vasopressin at a fixed rate of 0.04 units per minute, followed by titration of phenylephrine to maintain the blood pressure goal” (mean arterial pressure greater than 60 mm Hg, or systolic blood pressure greater than 90 mm Hg), she said.

To the best of the author’s knowledge, (this is) the first clinical study to look at dopamine versus norepinephrine in a randomized, controlled fashion,” she said in an interview. “Our study was designed to look at mortality as a primary end point. During an interim safety analysis, we found a difference in arrhythmogenicity,” she said.

In all, 31% of the dopamine group experienced dysrhythmias, compared with 3% of the norepinephrine group, a statistically significant difference. There was no significant difference in mortality (dopamine 49.5%).

“Given the significant difference in the incidence of cardiac dysrhythmias associated with dopamine administration in septic shock patients, consideration should be given to using norepinephrine over dopamine as a first-line vasopressor agent in septic shock, especially in patients with a history of arrhythmia or cardiac problems,” Dr. Simon Grahe said.

Patients with a history of prior arrhythmias had a statistically significant greater likelihood of developing cardiac dysrhythmias when on vasopressors,” she said.

**Higher Rate of Dysrhythmias Found in Dopamine Patients**

**Norepinephrine might be best for septic shock.**

BY BOB BABINSKI

Elsevier Global Medical News

**MONTRÉAL** — Proper nutrition for critically ill patients significantly reduces infection rates and hospital length of stay, Dr. Paul E. Marik, FACP, said at the annual meeting of the American College of Chest Physicians. Changes in medical management were recorded following each echo and compared with decisions made after the second echo.

“Although the numbers that I present are small, I feel that changing the therapeutic intervention in 37.9% of patients in shock is important,” the author said. “Also, the use of echocardiography by intensivists will have a major impact on how they treat patients in the early phases of shock.”

If there is a bowel, use it,” a smiling Dr. Marik told the attendees, advocating the value of enteral feeding. “There is no disease process that benefits from starvation,” said Dr. Marik, director of pulmonary and critical medicine at Jefferson Medical College, Philadelphia.

In a systematic review of 13 studies of 753 hospitalized patients who were either critically ill or injured, he found a significant benefit to early versus delayed feeding (Crit. Care Med. 2001;29:2264-70).

The review included hospitalized adults in one of the following categories: postoperative, trauma, head injuries, burns, or medical intensive care unit.

Those who received enteral feeding within 16 hours after surgery were less likely to develop infections than those whose feeding was delayed (relative risk of 0.45). That same group also saw a significant mean reduction in hospital length of stay. To the extent that the ICU is a resource intensive care unit, if the patient is intolerant, feeding should be done with a small bowel tube, he said.

As for the quantity of nutrient intake, his evidence-based recommendations suggest that feeding begin at 13%–66% of the calculated intake. That level is determined using the following formula: 15-20 kcal/kg per day and 40-60 cc/hour. This level should be maintained for 3-5 days. As the patient improves, the level can be increased to full intake over another 3-5 days. Full intake is determined by this formula: 20-25 kcal/kg per day, and 60-75 cc/hour.

“As for the quantity of nutrient intake, his evidence-based recommendations suggest that feeding begin at 13%–66% of the calculated intake. That level is determined using the following formula: 15-20 kcal/kg per day and 40-60 cc/hour. This level should be maintained for 3-5 days. As the patient improves, the level can be increased to full intake over another 3-5 days. Full intake is determined by this formula: 20-25 kcal/kg per day, and 60-75 cc/hour.”

Early Echocardiogram May Alter Shock Tx

**Postop Infection Rate Dropped With Early Enteral Feeding**

Don’t delay feeding even in critically ill patients.

**Surgical Procedures Included**

- Hepatobiliary
- Pancreatic
- Cardiorespiratory
- Thoracic
- Plastic
- Oncologic

**As for the quantity of nutrient intake, his evidence-based recommendations suggest that feeding begin at 13%–66% of the calculated intake. That level is determined using the following formula: 15-20 kcal/kg per day and 40-60 cc/hour. This level should be maintained for 3-5 days. As the patient improves, the level can be increased to full intake over another 3-5 days. Full intake is determined by this formula: 20-25 kcal/kg per day, and 60-75 cc/hour.**
Atrial Pacing Didn’t Dent Sleep Apnea, Hypopnea

BY MARTHA KERR
Elsevier Global Medical News

A trial of atrial overdrive pacing involved patients with moderate to severe sleep apnea, who were suffering from sleep apnea and hypopnea syndrome, with nasal continuous positive airway pressure showed strong efficacy, according to the report by Dr. Emmanuel N. Simtraitakis and colleagues at Heraklion (Crete) University Hospital, Greece, implanted dual-chamber pacemakers in 16 patients with moderate to severe sleep apnea, documented sleep-related bradycardia, and normal ventricular function (N. Engl. J. Med. 2005;353:2568-77).

 Patients had a mean baseline apnea-hypopnea index of 49 and had at least two self-reported syncopal episodes in the preceding year. Diagnosis of sleep with apnea or hypopnea was confirmed on polysomnography.

All pacemakers were initially programmed for atrial overdrive pacing, with pacing at a rate of greater than 15 beats per minute. After 48 hours, half of the patients had their pacemakers programmed for atrial overdrive pacing, with pacing at a rate of greater than 15 beats per minute or greater than their normal nocturnal heart rate. The rest of the patients remained on backup atrial pacing plus nasal continuous positive airway pressure (n-CPAP).

One month later, the two groups switched therapies. The researchers followed the patients for another month. Atrial overdrive pacing had virtually no effect on the average apnea-hypopnea index at 1 month, which rose from 49 at baseline to 49.2. The increase was not statistically significant. In contrast, n-CPAP significantly improved the average apnea-hypopnea index after 1 month of therapy, which fell from 49 at baseline to 27. Arousal index, desaturation index, and all other variables measured except total sleep time showed improvement with n-CPAP, while atrial overdrive pacing had no measurable effect on the variables, the researchers said.

“We were unable to show any beneficial effect of pacing in reducing the number of episodes of apnea or hypopnea per hour,” the investigators wrote.

The findings of the study, however, may not apply in general to all patients who are suffering from obstructive sleep apnea-hypopnea syndrome, they cautioned.

The failure of atrial overdrive pacing to improve symptoms “suggests that overdrive pacing is likely to have a very limited role in this setting,” Dr. Daniel J. Gottlieb of Boston University said in an accompanying editorial (N. Engl. J. Med. 2005;353:2604-6).

“Phenotypes will be identified in which modification of neuromuscular factors will play a useful therapeutic role,” he added.

Adjustable Oral Appliance Cut Snoring Rate and Loudness

SURPRISINGLY, the device reduced palatal snoring, measure overnight snoring. This device records continuous pulse-oximetry data and makes an acoustical recording from a microphone positioned near the patient’s upper lip. Proprietary algorithms and the recorded sounds to determine the amount and anatomic site of snoring.

After using the TAP II for 3 weeks, snoring decreased from 364 to 216 events per hour. Average and maximal snoring loudness decreased about 5 dB each, which was statistically significant.

The percentage of all snoring sounds originating from the palate decreased from 66% to 47%. The percentage of snoring originating from the tongue base increased from 11% to 16.6% (not statistically significant), while the number of tongue-based events decreased.

“The TAP II is effective in reducing palatal snoring as measured by an objective test, and this demonstrates that oral appliances can have dynamic physiologic effects at airway levels other than the tongue base,” Dr. Mair said.

The study enrolled only 10 patients with significant obstructive sleep apnea, thus decreasing its power to detect changes in sleep apnea with oral appliance use.

After the study period, the respiratory disturbance index declined from 14.4 to 10.4, not quite reaching statistical significance. The apnea index declined from 5.1 to 3.2; the hypopnea index declined from 10.2 to 7.6. Patients reported a low amount of jaw and tooth pain associated with TAP II and had good compliance during the study period. However, after completion of the 3-week study patients were followed for 6 months, during which time compliance declined, with about 50% of patients reporting use of the TAP II on at least 50% of nights.

African Americans Need Education on Sleep Apnea Risks

BY ELAINE ZABLOCKI
Elsevier Global Medical News

Los Angeles — African Americans at increased risk for obstructive sleep apnea, compared with whites, but their bed partners are less likely to encourage them to seek treatment, Dr. Michael Friedman reported at the annual meeting of the American Academy of Otolaryngology–Head and Neck Surgery Foundation.

Studies on the incidence of sleep apnea have focused primarily on whites, leaving the incidence among African Americans unknown, Dr. Friedman said. However, hypertension rates are twice as high among African Americans as among whites.

"The comorbid conditions—hypertension, obesity, and cardiovascular disease—need the create the need and treat sleep apnea in African Americans," said Dr. Friedman, chairman of the section of head and neck surgery at Rush University Medical Center, Chicago.

Most people don’t seek treatment for sleep apnea on their own. Instead, they tend to come in at the urging of their bed partner. Dr. Friedman and his colleagues hypothesized that differences in social attitudes might affect the likelihood of people seeking treatment.

The investigators interviewed 236 people, most of them aged 25-55 years. Investigators offered a free ear, nose, and throat screening plus a gift to couples at the Chicago Health Fair, attended by 80% of African Americans.

Participants received a simple physical exam and answered questions on the frequency and intensity of snoring, daytime sleepiness, observed apnea, and morning headaches.

Participants were asked questions to evaluate their attitudes about snoring. One partner was identified as the actual study participant; the other partner agreed with the first partner’s answers to the screening questions.

The study group included 287 people of African American descent and 236 of white descent. There were no differences between the two groups in terms of age or sex distribution, but the mean body mass index in African Americans was significantly higher, compared with whites.

Neck size tended to be larger among African Americans. Snoring severity, measured on a subjective 10-point scale, was found to be about 1 point more severe in African Americans.

One partner’s examination demonstrated that African Americans tended toward larger tonsils and higher Friedman tongue positions (FTP), both increasing the likelihood of obstructive sleep apnea. Friedman tongue positions III and IV indicate hypopharyngeal obstruction and 79% of African Americans had either FTP III or FTP IV, while only 55% of whites had FTP IV.

When the researchers asked questions about attitudes towards snoring, they found significant differences. More than 10% of African Americans considered snoring to be normal, compared with 18% of whites. African Americans were less likely to leave the room, or to be asked to leave the room due to snoring.

“African Americans have more severe symptoms. They are more likely to consider snoring to be normal and less likely to be asked to leave the room due to snoring,” Dr. Friedman said.

“The question is, are they therefore less likely to seek treatment? One conclusion that we can make is that African Americans need more education about obstructive sleep apnea and encouragement to seek diagnosis and treatment,” he said.
FDA Advisory Targets Long-Acting Bronchodilator Safety

**Products ‘may increase the chance of severe asthma episodes and death when those episodes occur.’**

**BY ELIZABETH MECHCATIE  
Elsevier Global Medical News**

Long-acting \( \beta_2 \)-adrenergic agonists should not be the first medicine physicians prescribe for asthma and should be added to treatment only when patients do not adequately respond to other asthma medications, according to a public health advisory issued by the Food and Drug Administration in November.

Although these bronchodilators reduce the frequency of asthma episodes, they “may increase the chance of severe asthma episodes and death when those episodes occur,” the advisory said.

The FDA has asked that the manufacturers of the long-acting \( \beta_2 \)-adrenergic agonist (LABA) products update their product labels with these warnings and provide a medication guide explaining these risks to patients when they fill or refill prescriptions.

The three products available in the United States are formoterol fumarate inhalation powder (Foradil) and salmeterol xinafoate inhalation powder (Serevent), which contain the LABA alone, and Advair Dokus, which contains both salmeterol and the inhaled corticosteroid (ICS) fluticasone. All three products are approved for maintenance therapy and prevention of bronchospasm in adults, adolescents, and children, but not for acute relief of bronchospasm.

GlaxoSmithKline, the manufacturer of Advair and Serevent, disagrees with the proposed labeling changes, it said in a statement. The changes are “inconsistent” with the National Heart, Lung, and Blood Institute (NHLBI) asthma treatment guidelines and with the standard of care for asthma therapy, “which could put many patients at risk of uncontrolled asthma,” the statement said. Further, the company is working with the FDA to “address the differences of opinion about how best to communicate the benefit risk profile of these medicines for optimal patient care.”

A spokesperson for Novartis, the manufacturer (with Schering-Plough) of Foradil, said the company was working with the FDA on the most appropriate language for the package label and medication guide.

(The LABAs are also approved for chronic obstructive pulmonary disease, but the advisory says that information is not available to determine whether similar concerns exist when LABAs are used to treat COPD or exercise-induced wheezing.)

The latest NHLBI asthma guidelines, published in 2002, recommend an LABA and ICS as the treatment of choice for patients with moderate or severe persistent asthma. The guidelines do not suggest that such patients have to fail treatment with an ICS first, said Dr. Harold S. Nelson, a member of the expert panel and senior staff physician at the National Jewish Medical and Research Center in Denver.

Treatment with an ICS alone is recommended for mild persistent asthma, Dr. Nelson said in an interview. The NHLBI panel recommendations were based on a large number of studies that directly compared medication regimens that added an LABA to low-dose ICS with those that doubled or more than doubled ICS dose, and for every outcome, the LABA plus low-dose ICS was superior, he added.

Dr. Nelson said he was concerned that the advisory could result in inferior treatment, with some patients with moderate to severe persistent asthma being taken off an LABA, and that the patient medication guide will be unnecessarily alarming and could result in some patients stopping the drug without consulting their physician.

Dr. Nelson also said he was concerned that the advisory implies a causality that has not been established.

The advisory refers to the Salmeterol Multicenter Asthma Research Trial (SMART)—a large, randomized, double-blind trial of asthma patients begun in 1996 by GlaxoSmithKline—which compared the safety of salmeterol with that of placebo when added to the usual asthma treatment.

The trial was stopped early in January 2003, after 30,000 patients had been enrolled, when an interim analysis found 13 asthma-related deaths over 28 weeks of treatment among those on salmeterol (0.10%) vs. 3 in those on placebo (0.02%). The increase in risk resulted in the addition of a black box warning to the label of salmeterol products in August 2003.

Adding Acetylcysteine May Slow IPF Progression

BY SHARON WORCESTER
Elsevier Global Medical News

The addition of the antioxidant acetylcysteine to the standard treatment for idiopathic pulmonary fibrosis (IPF) may improve the patients’ quality of life, according to a study published in the Journal of the American Thoracic Society.

In this phase II trial, 182 patients with usual interstitial pneumonia were randomized to receive standard treatment with prednisone and azathioprine plus placebo or the standard treatment plus 600 mg acetylcysteine given three times daily.

The absolute difference in the change from baseline among the 71 patients in the acetylcysteine group and the 68 in the placebo group was 1.86 mg/dl, compared to 1.86 mg/dl in the placebo group.

The number and type of adverse events were similar in the two groups, except those in the acetylcysteine group had a significantly lower rate of bone marrow toxicity. Mortality at up to 1 month after treatment completion was also significantly lower in the acetylcysteine group and 11% for the placebo group. Dr. Maurits Demedts of Katholieke Universiteit Leuven (Belgium) and colleagues reported.

Although the beneficial effects of acetylcysteine did not translate into a significant survival benefit, the results of this multinational, double-blind study have clinical relevance, according to the investigators.

“The results support the hypothesis that acetylcysteine has a potential role in the treatment of IPF,” said Dr. Guillaume Remy-Jardin, director of the division of occupational medicine at the University of Liège, Belgium, and collaborating investigator. A placebo group for these drugs.

High-Res CT Shows Effects of Allergen Long After Exposure

BY PATRICIA WENDLING
Elsevier Global Medical News

CHICAGO — For the first time, researchers have shown that lung function remains impaired in people with asthma for up to 22 hours after exposure to cat allergens, even after outward symptoms have abated. High-resolution CT showed significant air trapping, suggesting that constriction and inflammation of the small airways remain long after initial exposure, Jared W. Allen, Ph.D., reported at the annual meeting of the Radiological Society of North America.

High-resolution CT analysis is a safe, noninvasive means of evaluating these airways that is not possible with conventional pulmonary tests, said Dr. Allen, a researcher at the University of California, Los Angeles.

He presented data from a pilot study in which 10 patients with known allergy to cats were evaluated with pulmonary function tests and high-resolution CT scans before and 6 and 22 hours after allergen exposure. The baseline and 22-hr CT studies were performed before and after methacholine challenge testing. Patients were hooked up to a spirometer when they entered the CT scanner.

All scans were acquired on the same scanner. The lungs were segmented into 12 regions of interest from which lung attenuation curves were derived.

All patients exhibited an immediate decline (mean decrease 30%) in forced expiratory volume in 1 second (FEV1). At 22 hours after exposure, the decline in FEV1 was no longer significant (5%). Median and 10th percentile lung attenuation curves, however, remained significantly left-shifted at 22 hours, indicating increased air trapping (mean change –15.88 HU and –10.42 HU, respectively).

Methacholine challenge testing caused a further shift of the median (–16.85 HU) and 10th percentile (–12.81 HU) compared with baseline.

New Drug Topped Bupropion for Smoking Cessation

BY MITCHEL L. ZOLER
Elsevier Global Medical News

DALLAS — The first agent from a new drug class was safe and effective in helping patients stop smoking in three phase III trials that involved more than 3,000 patients.

Treatment with varenicline, a selective nicotinic acetylcholine receptor partial agonist, led to smoking quit rates that doubled what was achieved with bupropion (Zyban, GlaxoSmithKline) and quadrupled the rate with placebo in a pair of acute therapy studies, Serena Tonstad, M.D., reported at the annual scientific session of the American Heart Association.

The third study showed that 24 weeks of treatment with varenicline was safe and better maintained abstinence from smoking than a 12-week course of the drug.

All of the studies were sponsored by Pfizer Inc., which is developing the drug and plans to market it as Champix. The phase III data presented at the meeting was part of a new drug application submitted to the Food and Drug Administration in November, according to a statement released by Pfizer. Dr. Tonstad has received honoraria from Pfizer as a speaker and consultant.

Varenicline was designed by researchers as a nonnicotine agent that is both an antagonist and partial agonist for the nicotine receptor. As an antagonist, the drug prevents nicotine from binding to its receptor, thus reducing the positive reinforcement that usually accompanies smoking and “breaking the cycle of addiction,” said Dr. Tonstad, department of preventive cardiology, Ullervå University Hospital, Oslo.

The drug’s agonist side means that it also partially activates the nicotine receptor, which blunts withdrawal symptoms and curbs craving after patients stop smoking.

The two acute treatment studies had an identical design and were done at centers in the United States. Each study included slightly more than 1,000 people who smoked about a pack of cigarettes daily and had smoked for about 25 years. All the participants were motivated to quit.

They were randomized to treatment with 1-mg varenicline b.i.d., 150-mg bupropion b.i.d., or placebo. After receiving their assigned agents for 7 days while continuing to smoke, the participants were told to stop smoking on day 8. Treatment continued for another 11 weeks, during which they had weekly examinations and attended brief weekly motivational support sessions that focused on the behavioral aspects of smoking cessation.

Successful cessation, the primary end point of both studies, was defined as not inhaling even a single puff of cigarette smoke during the last 4 weeks of treatment. Abstinence was monitored during weekly clinic visits by expired carbon monoxide levels.

In both studies, during weeks 9-12 of treatment, 44% of those in the varenicline group abstained from smoking, as did 30% of those in the bupropion group and 18% of those in the placebo group.

Statistical analysis calculated that the odds ratio of smoking cessation was nearly fourfold higher in the varenicline group than in placebo patients, and nearly twice as high in the varenicline group than in those receiving bupropion—the only drug approved in the United States for smoking cessation. All of the rate differences between the varenicline and comparator groups were statistically significant.

A secondary end point for both studies was the rate of continued quit rates during the 44-week period starting with the ninth week of treatment and continuing to 1 year after the start of the study. (Participants were treated for the first 4 weeks and during weeks 9-12, and then were off treatment for the next 40 weeks.)

Abstinence rates during this period were about 22% for the varenicline-treated people in both groups, compared with a 16% rate in those treated with bupropion and about 9% in those who got placebo.

The third study, done in the United States and in sites in other countries, began with 1,927 people who received 1-mg varenicline b.i.d. on an open-label basis for 12 weeks. At the end of this period, 1,236 (64%) patients remained abstinent from smoking and were eligible for the maintenance phase. The second half of the study randomized 662 people to receive varenicline for a second 12-week period, and 604 were randomized to placebo.

During weeks 13-24, continuous abstinence from smoking was achieved at a rate of 75% in the varenicline group and a rate of 50% in the placebo group. Similarly, smokers who abstained from smoking were also more likely to remain off treatment for at least 1 year after the start of the study. (Participants were treated for the first 4 weeks and then were off treatment for the next 40 weeks.)

Abstinence rates during this period were about 22% for the varenicline-treated people in both groups, compared with a 16% rate in those treated with bupropion and about 9% in those who got placebo.
**Tool Flags Uncontrolled Asthma**

BY BETSY BATES
Elsevier Global Medical News

ANAHEIM, CALIF. — A simple, seven-questions pictorial tool can give a pediatrician an instant snapshot of whether a patient’s asthma is well controlled at the time of an office visit.

Children aged 4-11 years and their caregivers can complete the Childhood Asthma Control Test in 1-2 minutes.

The answers reliably predict which asthma patients are doing well and which require focused attention, reported Dr. Andrew H. Liu, a pediatric allergist and immunologist at the National Jewish Medical and Research Center in Denver.

The questionnaire was developed by Dr. Liu and 11 other pediatric allergy and pulmonology specialists whose working group initially tested 21 questions on 344 pediatric asthma patients and their caregivers to see which correlated best with asthma control, as defined by lung function and clinical assessments by specialists.

The cohort included children with moderate to severe asthma (38%), as well as many with mild to moderate asthma. Almost a third of the patients were considered by specialists to have asthma that was controlled poorly or not at all.

Results of a validation study were presented at the annual meeting of the American College of Allergy, Asthma, and Immunology.

Four questions answered by children (with pictures to assist them) and three questions answered by caregivers were most predictive of asthma control in a subset of 257 children randomly chosen from the sample. (See box.)

**Asthma Control Questionnaire**

**For Children Aged 4-11**

- **How is your asthma today?**
  - Very bad (0).
  - Bad (1).
  - Good (2).
  - Very good (3).

- **How much of a problem is your asthma when you run, exercise, or play sports?**
  - It’s a big problem. I can’t do what I want to do (0).
  - It’s a problem and I don’t like it (1).
  - It’s a little problem but it’s OK (2).
  - It’s not a problem (3).

- **Do you cough because of your asthma?**
  - Yes, all of the time (0).
  - Yes, most of the time (1).
  - Yes, some of the time (2).
  - No, none of the time (3).

- **How much of a problem is your asthma because of nighttime awakenings?**
  - Yes, all of the time (0).
  - Yes, most of the time (1).
  - Yes, some of the time (2).
  - No, none of the time (3).

Source: Dr. Liu

**For the Caregiver**

- **During the past 4 weeks, on average, how many days did your child have any daytime asthma symptoms?**
  - Every day (0).
  - 19-24 days per month (1).
  - 11-18 days per month (2).
  - 4-10 days per month (3).
  - 1-3 days per month (4).
  - Not at all (5).

- **During the past 4 weeks, on average, how many days did your child wheeze during the day because of asthma?**
  - Every day (0).
  - 19-24 days per month (1).
  - 11-18 days per month (2).
  - 4-10 days per month (3).
  - 1-3 days per month (4).
  - Not at all (5).

A grant from GlaxoSmithKline provided funding for the study.
CHEST Physician: New Directions, Enduring Values

By W. Michael Alberts, MD, FCCP

As ACCP staff members gathered on stage after the Jeopardy-style CHEST Challenge, Al Lever, ACCP Executive Vice President and CEO, held up a sign to them with the answer written on it: “5,000.”

“So, what is the question?” he asked.

Most of us knew we were very close to breaking an attendance record, and Al confirmed our suspicions. CHEST 2005 registration had gone over the top and surpassed the magic number of 5,000 professional registrants. And when the final figures came in, the total, all-inclusive attendance topped 7,500.

CHEST 2005 broke the attendance record and provided an unmatched venue of education, innovation, conversation, and celebration.

Education? ACCP sets the standard for clinical chest medicine education. CHEST 2005 even raised that standard and offered attendees an unmatched, comprehensive menu of learning opportunities: postgraduate courses; satellite symposia; more than 170 general sessions; literature reviews; curriculum-based learning sessions; ABIM SEP study sessions; cram courses for board review; keynote, honor, and memorial lectures presented by notable experts in their respective fields; and evidence-based guideline sessions and updates.

Innovation raised its intriguing head throughout CHEST 2005. Attendees watched demonstrations of simulation education in the exhibit hall, where patient models were used that simulated clinical experiences in chest medicine. Elementary school children participated in hands-on lung-learning experiences during the annual ACCP Industry Advisory Council and CHEST Foundation Community Outreach Event. Hundreds of posters and case reports presented new procedures, new results, and new ideas.

Conversation is never lacking at a CHEST meeting. The 2005 Convocation was the largest ever, comprising more than 170 participants, where friends, old and new, welcomed the new FCPs and convened among themselves about their professions, their families, and their futures. Panel discussions spurred sessions full of enthusiasm, and meet-the-professor opportunities offered discourse with the experts. The President’s Reception and Reunions and the NetWork open meetings allowed time for groups sharing.

CHEST 2005 tops the magic number of 5,000 professional registrants. Patient models simulate clinical experiences in chest medicine.
Similar interests to convene, converse, and collaborate.

Our CHEST 2005 partner societies, the Canadian Thoracic Society and the American Association for Bronchology, met for their annual assemblies, and ACCP leaders met with many other partnering societies, including the European Respiratory Society, the American Thoracic Society, and the American Association of Critical-Care Nurses, to discuss mutual goals.

And finally, the celebrations—and there were many.

We celebrated A. Jay Block, M.D., Master FCCP, and his accomplishments, as he retired as editor-in-chief of CHEST. We praised and acknowledged renowned leaders in science and medicine through honor and memorial lectures and awards. We welcomed 137 new FCCPs into the College and a new President, W. Michael Alberts, M.D., FCCP.

And we celebrated winners—lots of them. Awards for humanitarian service, clinical research, young investigators, best posters, best case reports, CHEST Challenge, lung health walk/run winners, exhibit hall bingo winners.

Visit our Web site (www.chestnet.org, www.chestfoundation.org) to see all of these winners!

Stay tuned for CHEST 2006, Oct. 21-26, in Salt Lake City, Utah, which will take us to even greater heights.
M ost physicians in the United States think of continuing medical education as those activities they attend weekly in their local medical community and, occasionally, at some national meetings. Often, these educational activities center around lecture-based teaching, as most physicians are accustomed to this teaching methodology. Today, however, we are in an environment of increased amounts of information, and it comes to us in many forms. Technical systems are one of the key drivers behind this increase, yet most knowledge transfer in medicine still relies upon lectures and medical journals. Although these two learning methodologies do provide learning opportunities, they do not necessarily address physicians’ need to manage information and determine different methodologies’ impact on physician behavior change. A study by Geoff Norman, Ph.D., of the McMaster University psychology department, indicated that physician learning strategies must include a structured practice audit, the use of simulation exercises with standardized patients, and patient and colleague feedback. Moving physicians toward these types of learning strategies is challenging, as evidenced by Dr. Jere-my Grimshaw and colleagues of the Ottawa Health Research Institute, who noted that most physicians currently spend less than 1 hour per week updating their knowledge base. The overwhelming denominator is time. Continuing medical education, however, must evolve as physicians’ needs are changing. An increased emphasis upon outcomes, certification and recertification requirements, accreditation and license scrutiny, and validation of educational learning experiences are driving the change in physician needs.

Professional societies will be instru-metal in helping their physician members better understand and prioritize this learning evolution in continuing medical education. Specifically, physicians will want to know how best to meet the increasing demands being placed upon them in the most efficient way possible. As a result, physicians will need to be provided useful tools that will enable them to be more comfortable with different learning methodologies that are more focused upon self-assessment, personal techniques of reflective learning, outcomes analysis, root-cause analysis, and other areas. Reform for continuing medical education is inevitable. This evolution stems from multiple sources, with a focus upon patient safety, competency, lifelong learning needs, and physician behavior change. I would encourage that this evolution be seen not as a complexity in one’s career, but as one that takes the desire to obtain the latest information and knowledge to increase the quality of health care for patients, who are looking to the medical community to serve their needs.

References
Norman GR, Shannon SI, Marrin LM. BMJ 2004; 328:999-1001

The ACCP Institutes

The ACCP Institutes are centers of excellence created to provide an opportunity to focus the combined resources of current ACCP professional resources, The CHEST Foundation, other societies, patient advocacy groups, and industry representa-tives. The Institutes will develop new educational and research activities for our members and all health care professionals who are committed to excellence in critical care and sleep medicine. As a valued member of the ACCP, you benefit from all the Institutes’ newly developed professional resources. Visit the Institutes’ Web site at www.chestnet.org/institutes.

At CHEST 2005 in Montreal, the Institutes again proved successful in continuing to communicate their vi-sion, mission, and project goals to ACCP membership.

The ACCP Practice Management Department Is Working for You

Take advantage of Practice Management Department (PMD) resources to run a more efficient practice. Purchase the expanded and reorganized 10th edition of Appropriate Coding for Critical Care Services and Pulmonary Medicine, 2006. Recently, several ACCP members contacted the PMD for help with Medicare documentation audits of their evaluation and management services, particularly critical care CPT codes 99291 and 99292. Despite very long documentation (4-5 pages!), basic infor-mation was missed, such as noting total time spent for these time-based codes. In addition, document why and how the patient is critically ill. For example, document not only what you are doing, but describe all the organ systems failing at risk, not just respiratory failure. Appropriate ICD-9-CM diagnostic coding with your CPT 99291 supports the medical necessity of the visit.

Codi ng Changes
Some new ICD-9-CM codes that became effective on October 1, 2005, are: new sleep codes, 147.00-147.4; a new code, V46.13, encounter for weaning from respiratory ventilator; and a new code, 799.82, for hypoxemia. Relevant CPT changes include the deletion, effective Jan. 1, 2006, of inpa-tient consultation codes 99261-99263 and confirmatory consultation codes 99271-99273. In addition, Nursing Facility Care codes for new or established patients have been deleted and replaced by CPT 99304-99310.

For the American Medical Association CPT and RVS Specialty Society Update Committee (RUC), ACCP has very active advisors. Steve Peters, MD, FCCP, is the CPT Advisor, and Edward Diamond, MD, FCCP is the RUC Advisor. Scott Manaker, MD, FCCP is a RUC member. Diane Krier-Morrow, MBA, MPH, CCS-P, staffs their efforts for CPT in collaboration with the American Thoracic Society Advisors: Stephen Hoffmann, MD, FCCP for CPT and Alan Plummer, MD, FCCP, for ATS.

ACCP hosted a meeting of pul-monary, critical care, and sleep Con-tractor (Carrier) Advisory Committee (CAC) representatives to state Medicare contractors (formerly called carriers) at CHEST 2005. ACCP is still trying to identify all the CAC representatives and is missing several states. We are begin-nning quarterly conference calls in Janu-ary and April. If you fulfill this role for your state and have not been contacted by us, please let us know.

For any coding and reimbursement or practice management issues, contact Marla Brichta, ACCP, at (847) 498-8364 or mbrichta@chestnet.org.
The ACCP and The CHEST Foundation Respond to Hurricane Disasters

ACCP members have responded generously to The CHEST Foundation’s Beyond the First Response Matching Gift Fund. The proceeds of the fund will be used to create a special 2006 Humanitarian Awards Program to support patient-care projects by members most affected by hurricanes Katrina, Rita, and Wilma.

ACCP Members and Friends Donate More Than $26,000, to Date
ACCP members have responded generously to The CHEST Foundation’s Beyond the First Response Matching Gift Fund. The ACCP is providing $25,000 to seed the fund, and The CHEST Foundation will match all donations, dollar for dollar, up to a total of $100,000.

ACCP members and friends have donated more than $26,000, to date.

Linking Physicians and Positions
An important component of the ACCP’s Beyond the First Response program is to provide an opportunity for members and other health-care professionals impacted by the hurricanes to find new positions.

Many professionals currently displaced from their homes, practices, and hospitals are looking for positions on an interim or permanent basis.

The CHEST Foundation, the ACCP’s partner and technology foundation for the ACCP online job board, Career Connection, has developed a Web site to help match physicians with positions.

This site also provides an opportunity for those who have created temporary positions, specifically for health-care professionals displaced by Hurricane Katrina, to post their positions at no charge.

Volunteer positions may be posted under HEALTHECAREERS Network’s new, permanent, volunteer category.

Employers who have permanent, full-time, paid positions are encouraged to continue to post them to the HEALTHECAREERS or the ACCP Career Connection site.

This service is available for physicians, nurses, and administration staff positions.

The CHEST journal continues to offer free classified print ads for those seeking positions. For more information, visit HEALTHECAREERS Web site at www.healthecareers.com/katrina.

Extending ACCP Membership and CHEST Subscriptions
Many members in the Gulf Coast area have been significantly impacted by the hurricanes.

To help during this difficult time, all ACCP membership renewals and CHEST subscriptions in Louisiana, Mississippi, and Alabama have automatically been extended 12 months.

Helping ACCP Members to Communicate and Connect
An Internet blog has been developed to meet the needs of ACCP members who wish to rapidly and easily communicate thoughts and experiences about Hurricane Katrina, its impact, and the recovery effort.

It serves as an important communication mechanism to either post or read information about events, special announcements, or contacts. It connects those looking for information, people, or assistance with those who may be able to help.

ACCP members are encouraged to participate and alert others to the site, especially those in the affected areas.

The blog can be accessed at www.chestnet.org/patients/katrina/index.php.

Reaching Smoking and Nonsmoking Students in Montréal

The third annual college outreach prompted a lively discussion of smoking’s consequences.

BY DIANE E. STOVER, M.D., FCCP
Chair, The CHEST Foundation

The third annual college outreach of The CHEST Foundation and ACCP took place on Halloween night at Bre-Beul College in Montréal, Quebec, during CHEST 2005.

In past years, we visited sorority women at Stetson University in Florida and the University of Washington in Seattle.

This year was a bit different, because we had a much smaller group than the usual 20-30 women usually present, and young men were in attendance as well.

As in the past, the discussions lasted much longer than anticipated, and, as always, were very lively, resulting in an exchange of information that benefited both the students and those of us who attended.

We started out by discussing the Clean Indoor Air Act that Canada will put into effect this year. Two young men who smoked had very different opinions about this law.

One student felt that it greatly enlightened upon his rights as a citizen of Canada and that it would make outcasts of smokers.

The other young gentleman smoker felt that it was a good law, and it may help him and others to cut down on smoking.

Interestingly, one of the major reasons he wanted to cut down was not for health reasons but because of the exorbitant cost of a pack of cigarettes in Canada, which is $8-$12 Canadian.

We had a long discussion about social smoking, which they considered safe, since it is felt to be nonaddicting and, after all, “not really smoking.”

We asked the students, “If it is not smoking, then what is it?”

There were no good answers to this question from any of the students. As we have witnessed in the past, the medical consequences of smoking are not a reality to most young people.

They either think that by the time they develop ill health effects from smoking, there will be a cure, or that it just will not happen to them.

However, one young man stated that his great aunt had laryngeal cancer from smoking, and the tracheostomy frightened him so much that it played a great role in his not smoking.

Additionally, he was an athlete and thought that smoking would impair his ability to excel in cycling.

One young woman, who only smoked socially and could not be convinced that it actually is harmful, was taken aback when told smoking causes premature wrinkling.

That, she stated, might make her think about smoking cessation, even while in clubs.

Another student was initially concerned about the health effects that smoking might have on his body.

He tried one at the age of 11 and, as he said, “nothing happened.” He actually felt better, calmer, and more alert.

Then he smoked another and another, and, still, “nothing happened.”; now it is 8 years later, and he is still alive and well.

When you are 19 years old, the concept of mortality is hard to conceive.

Just as we found in our outreach university visits in the United States, young people in Canada seem to have very little concern for the medical consequences of cigarettes and the great addicting power of nicotine.

They believe strongly that, as adults, they have the right to make the decision to smoke, and nobody should try to tamper with that decision.

At the conclusion of our meeting, we asked the students if there were any last questions.

The very outspoken male smoker asked, “So, after hearing all of this, what are you going to do about young people smoking?” We replied, “We will be persistent, aggressive, and relentless in helping young adults to make educated and informed decisions not to smoke.”

I would like to thank Virginia Reicher, N.P., and Patricia Folan, B.S.N., from Northshore University Hospital; Maritza Groth, from Winthrop Hospital, and Mohit Chawla, Rohit Khirbut, and Lewis Voight, from Memorial Sloan-Kettering Cancer Center, for accompanying me. Also, special thanks to Dr. Voight for translating during the outreach.

Cough Guidelines Debut in CHEST

“Diagnosis and Management of Cough: Evidence-Based Clinical Practice Guidelines” has been published as a supplement to the January issue of CHEST.

The guidelines include comprehensive recommendations for the diagnosis and management of cough in adults and children, specific recommendations for the prevention of whooping cough in adults, and comprehensive evidence-based recommendations for treating cough in children.

For more information or to view the Executive Summary for the guidelines, go to the ACCP Web site at www.chestnet.org.
Antibiotic Resistance Reduction: Is Prudence the Only Way To Control?

BY GLENN S. TILLOTSON, PH.D., FCCP, AND JOY CARROLL, B.S.

In 60 years since Sir Alexander Fleming said, “It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and the same thing has occasionally happened in the body.” Moral: if you use penicillin, use enough” (Fleming. Nobel Lecture. 1945. http://nobelprize.org/medicine/laureates/1945/fleming-lecture/html).

This approach was a reiteration of Dr. Ehrlich’s prescient lecture in 1913 (Ehrlich. Lancet 1913), and, yet, we still strive to ignore these prophesies.

Even recently, it has been shown that low doses of antibiotics, given often for long periods, will clearly select for the weakest link in a population and lead to resistance emergence (Guillemonet et al. JAMA 1998; 279:365).

In human medicine, 80 to 90% of antimicrobials are prescribed in the community setting, and some sources estimate that almost half are dubious in their appropriateness.

Indeed, the World Health Organization estimated that respiratory tract infections, which account for many of these prescriptions, account for over 94 disability-adjusted life years lost globally and are the fourth major cause of mortality.

Thus, many authorities espouse that the best way to stop or slow antimicrobial resistance is by using antibiotics less often.

Most experts agree that it is the widespread, poorly controlled use of these vital agents that has led us to where we are presently in the battle against microbes, a battle that the microbes are, unfortunately, winning.

Several recent publications have reported marked reductions in antibiotic use in various countries, and, yet, we seem rarely to look beyond the crude marker of not being able to treat pneumonia in time as a sign of a positive result. It is as though all we want to do is make resistant strains less common, without regard for the proven benefits of antimicrobial therapy.

The current fear, with regard to resistance, is that there are few signs of any new replacement antimicrobials in development, particularly in the community setting. However, we also hear that “resistance does not lead to poorer outcomes,” and several studies have used various measures to support this position.

One of the few studies to compare key, clearly measurable parameters over two time periods was undertaken in the United Kingdom, from 1993 to 1994 and 1999 to 2000 — between which times major efforts were undertaken by government and other bodies to reduce the amount of antimicrobials prescribed for respiratory tract infections (Price et al. Respir Med 2004; 98:17).

In the United Kingdom, pneumonia is responsible for over 10% of all deaths, most of which occur in the elderly (approximately 66,000 in 1999).

Moreover, there were over 79,000 hospital admissions due to community-acquired pneumonia, leading to almost a million patient-days in the hospital.

In the United States, the case-fatality rate associated with pneumonia is 8.8%. Typically, there is seasonal variability in both the morbidity and mortality associated with pneumonia, with the highest rates occurring in the winter months.

Influenza can add to this health-care burden. Indeed, this viral infection predisposes to bacterial infections, suggesting that excess winter mortality may be susceptible to changes in antibiotic prescribing.

During the mid 1990s, United Kingdom government agencies and medical societies developed campaigns to reduce the use of antibiotics, particularly in respiratory tract infections, in the belief that this would reduce and reverse the emergence of resistance.

For the periods 1993 to 1994 and 1999 to 2000, Price and colleagues examined the winter prescribing of antibiotics for specific respiratory tract codes, according to the IMS Health United Kingdom MediPlus® database (Price et al. Respir Med 2004; 98:17).

In parallel, the pneumonia mortality and influenza incidences were also collected for these time spans.

Negative binomial regression analysis was used to examine changes over time for mortality and other trends. A sequential model was also used to determine whether the contribution of influenza or antibiotic prescribing was associated with changes in pneumonia incidence.

The main observation from this analysis was a significant association between the extent of antibiotic use and winter pneumonia mortality.

Accounting for the incidence of influenza, a clear increase in deaths due to pneumonia occurred, while there was a decrease in antibiotic prescriptions written for respiratory tract infections.

There was a 50.6% increase in mortality between 1993 to 1994 and 1999 to 2000, concomitant with a 36% reduction in antibiotics prescribed over the same period. These findings were robust in the face of different analytic methods and approaches.

The authors do raise the question as to causality, due to the study design, and suggest that further studies are required to establish these findings.

They note, however, that the results have implications beyond the United Kingdom.

The myriad of programs designed to simply use fewer antibiotics need to be better assessed in terms of consequences beyond death alone. This type of analysis should be repeated in other countries where accurate health-care data are available.

Simply cutting back may not be the right solution to slowing the microbes’ adaptation.

Ehrlich pointed out in 1913 that the victory against the microbes will require that “we allow therapeutic treatment to come into action as early as possible, as under these circumstances, the full success is most easily and most surely attainable” (Ehrlich. Lancet 1913). Ehrlich recognized the need to “fritter fort et frapper vite” (hit hard and hit quickly).

In fact, the World Health Organization recommendations support this approach, suggesting the use of the most pharmacologically potent member of the relevant class of antibiotics for a short period to treat effectively and decrease the chance of developing resistance (World Health Organization. WHO/CDS 2000; 2:62).

Antibiotic resistance is unlikely to be overcome by innovative research by the pharmaceutical industry, which has had only two new classes approved by the Food and Drug Administration in the last 20 years.

Moreover, of the more than 550 drugs in current development, only six are novel antibiotics.

Simply reducing the amount of antibiotics prescribed is also not the only answer.

There are clearly deleterious consequences beyond excess mortality.

Measurement of death is a blunt parameter, because there are many other, possibly better, ways to assess the implications, positive and negative, of merely decreasing antibiotic use.

Perhaps now is the time to alter how we use these drugs, not just simply use less of them.

The application of Ehrlich’s century-old ideas, along with modern pharmacodynamics, may help maintain what we currently have, while we await new antimicrobials from industry and other responsible groups.

Glen S. Tillotson, PhD, FCCP

Vice President of Scientific and Medical Relations

Oscient Pharmaceuticals

Waltham, MA

Visitng Distinguished Scientist

Public Health Research Laboratory

Newark, NJ

Joy Carroll, BS

Oscient Pharmaceuticals

Waltham, MA

Deborah Shure, MD, FCCP

Editor, Pulmonary Perspectives

Aymarah Robles, MD, FCCP

Deputy Editor, Pulmonary Perspectives

Editor’s Insight

This thoughtful Perspective by authors with both academic and industry experience presents an important concept for our consideration in the difficult issue of antimicrobial resistance.

The bottom line to consider is that we need to use the most active drug in sufficient dosage as early as possible to both treat effectively and reduce resistance.

This advice may be counter to the common view that it is more cost effective to use less expensive antibiotics first and save the more powerful ones for more serious disease.

The data and ideas presented here give us reason to reconsider.

As the authors point out, more studies to determine the best approach are needed, and such studies need to consider both resistance and effective treatment.

Deborah Shure, MD, Master FCCP
The Affiliate NetWork has just completed another very successful year, providing educational and leadership opportunities for its members.

CHEST 2006 topics and partnering with other NetWorks. This subcommittee also will focus on asthma research awards, development of an Internet catalog of asthma resources, integration with the National Asthma Education and Prevention Program (sponsored by the National Heart, Lung, and Blood Institute), planning for the triennial World Asthma Meeting (to be held in 2007), and assisting with the ACCP Health and Science Policy Committee’s development of the occupational asthma clinical practice guideline.

More enthusiasts in these multidimensional areas are welcome.

The Cardiovascular Medicine and Surgery NetWork

The Cardiovascular Medicine and Surgery NetWork, formerly the Cardiovascular Disease and Hypertension NetWork, would like to announce its new name and more-encapsulating constituency.

This important name change is meant to increase diversity among our membership and improve the communication between cardiologists and cardiovascular surgeons. This change will also facilitate joint programming and more broadly appealing topics at future CHEST meetings.

We have also been working on a consensus statement project, called the Evaluation of Secondary Hypertension, which was recently approved by the Council of Committees. A small NetWork work group is currently writing this statement.

To learn more about this project, please contact us at networks@chestnet.org or visit our Web site at www.chestnet.org/networks/cdh/index.php.

We discussed several new projects for the upcoming year at our CHEST 2005 business meeting, and we are excited to get started and to share these ideas with you. If you are interested in joining our NetWork, becoming more involved, or simply hearing about what’s next, please contact us at networks@chestnet.org.

Chest Infections NetWork

Whether the next pandemic is 2 years or 20 years away, now is a good opportunity to examine the readiness of your health-care organization to deal with the situation. We can expect the following small but eye-opening list of pandemic scenarios.

1. The available supply of masks, gloves, and gowns could result in an 8-fold to 10-fold increase in your hospital’s incidence of high-risk patients. Your patient develops anaphylactic shock right before your eyes. You struggle to intubate her, but the airway edema is too severe to visualize your vocal cords. She arrests, and you begin CPR.

2. The complex nature of critical care medicine makes it an ideal area for skills enhancement using simulation scenarios.

3. Gain practical experience in critical care medicine and maintain a broad range of skills can be challenging because of the high-risk, high-stakes nature of the specialty and its patient population.

4. Simulation-based education has been employed in other high-risk professions for decades, and, in recent years, has generated significant interest in the medical community.

5. The development of high-fidelity patient simulators has provided a new opportunity to provide effective, experience-based medical education and performance improvement without jeopardizing patient safety.

6. The role of medical simulation in critical care education was a major topic of discussion at the CHEST 2005 Critical Care NetWork meeting.

7. The complex and procedure-based nature of critical care medicine makes it an ideal area for skills enhancement using simulation scenarios.

The NetWork voted unanimously to form a working group to examine ways to provide ACCP members with more simulation-based, critical care training opportunities.

If you are interested in joining this simulation working group, contact Jennifer Pitts at jpitts@chestnet.org.
Implanted Device Improved Heart Failure Management

**Dallas** — Management of heart failure patients with data from an implanted device that continuously monitors hemodynamic pressures led to a 25% reduction in total days spent in the hospital among patients with class III heart failure in a controlled study with more than 200 patients.

“The number of days spent in the hospital for decompensated heart failure is the principal driver of cost for heart failure treatment, and this was significantly decreased,” Dr. William T. Abraham said at the annual scientific sessions of the American Heart Association.

Use of the device in both outpatients and in hospitalized patients with heart failure “may make episodes of decompensation less extreme, and may help get patients out of the hospital more quickly,” said Dr. Abraham, professor and director of the division of cardiovascular medicine at Ohio State University in Columbus.

The finding came from new analyses of data collected in the Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure (COMPASS-HF) trial, which tested the clinical impact of managing patients with intracardiac pressure data collected by the implanted Chronicle device. The device is made by Medtronic, which submitted an application for licensing to the Food and Drug Administration last August that was still pending in January 2006.

The primary end point of the COMPASS-HF study was reported last March at the annual meeting of the American College of Cardiology. Although patient management guided by pressure data obtained by the Chronicle device led to a 22% cut in the rate of heart failure-related hospitalizations and emergency department and urgent-care visits, the drop was not statistically significant. However, several secondary analyses also were positive in favor of the device, including a new set of secondary analyses presented by Dr. Abraham, who is a consultant and investigator for Medtronic and has received honoraria from the company for speaking.

He cautioned that the COMPASS-HF study was not designed to provide definitive answers to these secondary analyses, and therefore the findings must be considered exploratory.

In addition, researchers at Medtronic have revised the results presented by Dr. Abraham based on more complete patient follow-up. The revised data showed that use of data from the Chronicle device cut the number of hospitalized days for heart failure by 20% instead of the 25% difference reported by Dr. Abraham.

In the COMPASS-HF study a total of 274 patients with advanced-stage heart failure underwent surgery to receive the subcutaneously implanted, hemodynamic monitoring device. The intracardiac pressure information collected by the device was used by physicians to guide the management of 134 patients for 6 months. The pressure information was withheld from the treating physicians in the control group of 140 patients. All patients in the study also received optimal medical care based on clinical findings. The benefits of applying information collected by the Chronicle device were greatest in the 85% of patients who entered the study with New York Heart Association class III disease. Those with class IV disease had much less benefit.

The reduction in hospitalized days using data collected by the implanted device was more marked if the analysis excluded outlier patients with hospitalizations that extended beyond 30 days. With this exclusion, use of the Chronicle device cut the total number of hospitalized days by 42% for all patients in the study, and by 38% in the class III-only patients.

Another secondary analysis examined the impact of using data from the Chronicle device on the rate of prolonged or short hospitalizations for heart failure. Among the class III-only patients, use of Chronicle information was associated with an average rate of 0.19 long hospitalizations (more than 5 days) every 6 months, compared with a rate of 0.31 long hospitalizations every 6 months in the control group, a 40% decrease in favor of the device. Use of the device also was associated with a 0.28 rate of short hospitalizations (5 days or less) every 6 months, compared with a rate of 0.42 short hospitalizations every 6 months in the control group.

Some experts expressed concern about paying for this intensive approach to patient management. “How should we decide which patients should get this?” commented Dr. Harlan M. Krumholz, professor of medicine and epidemiology at Yale University, New Haven, Conn.
Montreal — The field of sleep medicine may be awash with clinical promise, but chest medicine specialists must be alert to the challenging operational demands of running a sleep center, a panel of experts cautioned at the annual meeting of the American College of Chest Physicians.

“The industry revenue forecast is good,” said Dr. Richard K. Bogan, ACCP chairman and chief medical officer of SleepMed Inc. in Columbia, S.C. “The total business—equipment, therapy services, and sleep studies—is a $1.6 billion industry, and we’re seeing tremendous growth in sleep diagnostics.”

For hospital sleep labs, the market is only 51% saturated. That leaves plenty of capacity for growth, he said, with referrals coming from pulmonology, family practice, and ear, nose, and throat physicians, as well as from neurologists and cardiologists.

Then there’s all that snoring out there. About half of patients present for fatigue, so the primary care physicians try to figure out which ones need to be investigated to negotiate reimbursements with Medicare, he explained.

“More than 90% of patients with mood disorders have some sort of sleep complaint,” for example. “If you take patients with refractory depression, 40% may have sleep-disordered breathing,” he explained, “and until you correct their sleep abnormality, their mood disorder is not going to significantly improve.”

Planning for Success

A successful sleep laboratory starts with a successful business model. “Develop your business plan, make the process as efficient as you possibly can, look at your market area, and don’t hesitate to negotiate reimbursements with third-party payers,” Dr. Bogan said.

Sleep medicine centers face other legal and regulatory challenges. AASM accreditation, for example, requires that each port include a “treatment requirement,” Dr. Feinsilver said.

“Don’t just take what they give you, but rather, talk to them and show them the quality of your product, keeping in mind that Medicare reimbursement is more restrictive.”

Referrals don’t come just because of sleep-disordered breathing—only about 10% of patients visit their primary care or other referring physicians to discuss a sleep problem. They come because of fatigue, sleepiness, and mood changes, he explained.

“Many referring physicians have different reasons for sending patients, and you have to be aware of that in terms of your ability to network with those doctors.”

Referrals, added Dr. Bogan, are a major part of the successful business model.

Planning for Success

A successful sleep laboratory starts with a successful business model. “Develop your business plan, make the process as efficient as you possibly can, look at your market area, and don’t hesitate to negotiate reimbursements with third-party payers,” Dr. Bogan said.

Depending on age, 20%-40% of adults and 13% of children snore, Dr. Bogan said. Insomnia is a problem with 10% of patients in a primary care practice, and about 3% have restless legs syndrome. About half of patients present for fatigue, so the primary care physicians try to figure out which ones need to be evaluated. The problem—and opportunity—does not end there, said Dr. Bogan.

“The American College of Chest Physicians and SleepMed Inc. in Columbia, S.C. ‘The total business—equipment, therapy services, and sleep studies—is a $1.6 billion industry, and we’re seeing tremendous growth in sleep diagnostics.’”

18 Practice Trends CHEST Physician • JANUARY 2006

Sleep Medicine’s ‘Nightmares’

The four basic elements of malpractice under tort law are: duty—you have to have some sort of patient-physician relationship, but that doesn’t mean you ever met the patient; there has to be something you did wrong; there has to be some causation; and there has to be damage,” said Dr. Feinsilver, a pulmonologist at the State University of New York at Stony Brook. Sleep medicine centers face other legal and regulatory challenges. "AASM accreditation, for example, requires that each port include a ‘treatment requirement,’" Dr. Feinsilver said.

I think that’s absolutely wrong, and I would like to suggest that you not be in the habit of making treatment recommendations as part of your reports,” he cautioned.

Always remember that you as the director are responsible for patients, Dr. Feinsilver said. Know who is coming into your lab, get at least some basic information before the patient arrives, and decide what kind of test you’ll need to run, Dr. Feinsilver said. These basic steps are required for accreditation, he added.

Of Licenses and Reporting

Lab directors also have to worry about sleep technologist licensure, Dr. Feinsilver said.

“Some states require that your sleep techs be respiratory therapists, or that you have an RT on staff,” he explained. “Also, sleep techs are not considered health care professionals, and therefore not required by the AASM to be licensed or certified to accredit your lab.”

To complicate matters further, he said, all sleepy drivers and pilots must be reported to the proper licensing bureaus, “which can be a disaster,” Dr. Feinsilver said. When there’s no obligation to report, do not do so without the patient’s permission, he said, adding that a breach of medical confidentiality is allowable if it protects others from harm.

That can mean trouble, Dr. Feinsilver admitted. Fortunately, the American Thoracic Society stated in 1994 that physicians should report sleepy drivers if the patient is sleepy, has sleep apnea, and a history of an accident or an equivalent level of clinical concern, and if the physician can’t treat the patient within 2 months, he explained.

The Shape of Sleep to Come

Legal and reimbursement issues aside, the field of sleep medicine will survive, according to Dr. Charles W. Atwood Jr., FCCP. “The typical sleep lab of the future will be larger, and it will become a volume business, said Dr. Atwood, who is associate director of the University of Pittsburgh Sleep Medicine Center.

I think, interestingly, that insomnia will replace sleep apnea as the most common disorder sleep doctors deal with, and this will result in new models of care for this disorder,” he predicted.

Dr. Atwood also predicted that primary care doctors will play a much larger role in sleep diagnostics—but will refer most cases for management. “We will look back at how we used to be paranoid about primary care ‘taking over sleep’ and laugh,” he concluded.
Congress Delays Solution

Medicare • from page 3

Conference report, and the bill had to go back to the House for final approval.

“We got coal in our Christmas stocking,” not a positive update or a permanent fix to the formula’s sustainable growth rate. Dr. Larry Fields, president of the American Academy of Family Physicians, said in an interview. “Instead of electing to let [House] leaders hash it out and then let the bill go through, Rep. Nancy Pelosi [D-Calif.] demanded a roll call vote—which cannot be taken into consideration Jan. 31, when Congress returns.”

Without any legislation passed by both houses and signed by the president, the Centers for Medicare and Medicaid Services is bound by law to put the cuts into place, he added.

The hope is that Congress will wrap up its unfinished work on the omnibus appropriations bill by the end of January. Once the bill is signed, CMS would be required by law to not impose the cut.

“Patients and physicians will not un

THE HOPE IS THAT CONGRESS WILL WRAP UP ITS UNFINISHED WORK BY THE END OF JANUARY AND REQUIRE CMS BY LAW NOT TO IMPOSE THE CUT.

CONFIDENTIALITY AND PRIVACY: The information contained in this document is intended for use by healthcare providers and is protected by federal law against unauthorized use or disclosure.

understand why technicalities and politics are delaying congressional action to halt devastating Medicare cuts,” said Dr. C. Anderson, past president of the American College of Physicians. “We call on Congress and CMS to do whatever is necessary to stop the cuts,” he said, understanding why technicalities and politics are delaying congressional action to halt devastating Medicare cuts.

“In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse experiences have been reported during worldwide postmarketing experience:

In clinical trials using multiple doses of cefepime, 4127 patients were enrolled with the recommended dosages of cephalosporins for 30 years of age or under conditions that may compromise renal function, the maintenance dose should be reduced when cefepime is administrated to such patients. Continuing antibiotics administration for longer than 30 days may result in the emergence of resistant strains of enterococci, Pseudomonas aeruginosa, Acinetobacter, or other bacteria. Treatment with cefepime should be discontinued in patients who exhibit intolerance to this antibiotic.

Adverse reactions: In clinical trials of pediatric patients (See PRECAUTIONS: Pediatric Use). In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid in the removal of cefepime from the blood.

Hypocalcemia was more common among elderly patients. Clinical consequences from changes in serum calcium levels were not reported.

A similar profile was seen in clinical trials of patients’ patients. Clinical consequences from changes in either calcium or phosphate were not reported.

As with other cephalosporins, anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, eosinophilia, and thrombocytopenia, including pure red cell aplasia, has been reported. Although most cases of cefepime-induced neutropenia were observed during periods of treatment with cefepime, one case of pure red cell aplasia occurred in a patient receiving cefepime as part of a multiple drug regimen. Patients should be monitored for signs of hematologic toxicity, including white blood cell counts and differential, particularly in the elderly and patients with pre-existing conditions that may predispose to anemia or neutropenia.

Nephrotoxicity: Acute renal failure, including anuria, may occur after the administration of cefepime, but in most instances seems to result from a direct toxic effect of the drug rather than from superinfection or sepsis. Some cases of acute renal failure have been reported in patients with normal renal function who were given cefepime. In evaluating the role of cefepime in the causation of acute renal failure, consideration should be given to the possibility that the renal failure may be related to the underlying disease process. In patients in whom renal impairment is suspected, renal function should be determined prior to therapy with cefepime.

The following adverse events were noted to be probably related to cefepime during evaluation of the drug in clinical trials conducted in North America in 1521 cefepime-treated patients:

DOSAGE AND ADMINISTRATION

In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse experiences have been reported during worldwide postmarketing experience:

In patients with impaired renal function, the serum half-life of cefepime is prolonged compared to normal renal function. Therefore, dosage adjustments are required in patients with creatinine clearances of 10 to 50 mL/min. Cefepime is not cleared in dialysate fluid and therefore hemodialysis may be inadequate to remove cefepime from patients on dialysis. In these patients, a loading dose of 2 g IV should be used, followed by a maintenance dose of 1 g IV q8h for 4 days. During this time, the serum concentration of cefepime should be determined to confirm adequate dosage for the individual patient. The dosage regimen should be adjusted in patients who have a creatinine clearance < 10 mL/min.

In patients with impaired renal function (creatinine clearance < 30 mL/min), the serum half-life of cefepime is prolonged compared to normal renal function. Therefore, dosage adjustments are required in patients with creatinine clearances of 10 to 50 mL/min. Cefepime is not cleared in dialysate fluid and therefore hemodialysis may be inadequate to remove cefepime from patients on dialysis. In these patients, a loading dose of 2 g IV should be used, followed by a maintenance dose of 1 g IV q8h for 4 days. During this time, the serum concentration of cefepime should be determined to confirm adequate dosage for the individual patient. The dosage regimen should be adjusted in patients who have a creatinine clearance < 10 mL/min.

In patients with impaired renal function (creatinine clearance < 30 mL/min), the serum half-life of cefepime is prolonged compared to normal renal function. Therefore, dosage adjustments are required in patients with creatinine clearances of 10 to 50 mL/min. Cefepime is not cleared in dialysate fluid and therefore hemodialysis may be inadequate to remove cefepime from patients on dialysis. In these patients, a loading dose of 2 g IV should be used, followed by a maintenance dose of 1 g IV q8h for 4 days. During this time, the serum concentration of cefepime should be determined to confirm adequate dosage for the individual patient. The dosage regimen should be adjusted in patients who have a creatinine clearance < 10 mL/min.